

Special Issue

Biomarkers in Solid Tumors: Recent Advances and Challenges

Message from the Guest Editor

The landscape of solid tumor management has been fundamentally transformed by the discovery and clinical integration of biomarkers. From early detection and risk stratification to predicting treatment response and monitoring disease progression, biomarkers now serve as indispensable tools in precision oncology. The advent of high-throughput technologies, including next-generation sequencing, liquid biopsy and multi-omics approaches, have exponentially expanded our ability to uncover novel molecular signatures. These advances have enabled the identification of predictive biomarkers for targeted therapies and immunotherapies, ushering in an era of personalized medicine that offers improved outcomes for patients with cancers such as brain, breast, colorectal, lung, melanoma, pancreatic and prostate cancer. This Special Issue invites original research and reviews that explore both cutting-edge advances and persistent challenges in solid tumor biomarkers. By addressing these critical issues, we aim to accelerate the path toward more precise, accessible and effective biomarker-based oncology.

Guest Editor

Dr. Raghu Sinha

Department of Molecular and Precision Medicine, Penn State College of Medicine, Penn State Cancer Institute, Penn State Centre for Research on Tobacco and Health, Hershey, PA, USA

Deadline for manuscript submissions

31 December 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/277629

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).